4-butyrolactone has been researched along with Cancer of Ovary in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Contreras, JI; Karpf, AR; Kizhake, S; Kour, S; Natarajan, A; Rana, S; Robb, CM; Sonawane, YA; Zahid, M | 1 |
| Bamodu, OA; Deng, L; Hsiao, M; Huang, CC; Huang, WC; Lee, WH; Lin, YK; Liu, M; Tzeng, YM; Wu, ATH; Yeh, CT; Yuan, CC; Zucha, MA | 1 |
| Bao, HX; Gao, S; Gao, T; Hu, S; Johnston, RN; Li, QH; Li, T; Liu, H; Liu, J; Liu, SL; Liu, Y; Mastriani, E; Qi, Y; Shen, Z; Wang, H; Wang, S; Wang, X; Yu, M; Zeng, Z; Zhou, YJ | 1 |
| Fang, Z; Hao, E; Lang, F; Li, L; Liu, Y; Qu, J; Yin, H; Zhi, Y | 1 |
| Dikshit, A; Eilati, E; Gao, C; Gomes Filho, MA; Hales, DB; Klug, T; McGee, S; Small, C | 1 |
| Berger, W; Grunt, TW; Grusch, M; Lupu, R; Marian, B; Singer, CF; Wagner, R; Zielinski, CC | 1 |
| Ahmed, M; Al-Dayel, F; Al-Kuraya, KS; Alyan, A; Bavi, P; Hussain, A; Jehan, Z; Uddin, S | 1 |
| Grunt, TW; Karlic, H; Singer, CF; Tomek, K; Varga, F; Wagner, R | 1 |
| Colomer, R; Lupu, R; Mehmi, I; Menendez, JA; Oza, BP; Ropero, S; Vellon, L | 1 |
| Altomare, DA; Di Cristofano, A; Kuhajda, FP; Poulikakos, PI; Skele, KL; Testa, JR; Wang, HQ | 1 |
| Boyd, MR; McKee, TC; Meragelman, KM | 1 |
11 other study(ies) available for 4-butyrolactone and Cancer of Ovary
| Article | Year |
|---|---|
Symbiotic prodrugs (SymProDs) dual targeting of NFkappaB and CDK.
Topics: 4-Butyrolactone; Amines; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Drug Screening Assays, Antitumor; Female; Humans; Molecular Targeted Therapy; NF-kappa B; Ovarian Neoplasms; Piperazines; Piperidines; Prodrugs; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Sesquiterpenes; Signal Transduction; Structure-Activity Relationship | 2020 |
4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Topics: 4-Butyrolactone; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Autophagy-Related Protein 5; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Survival; Cisplatin; Cyclohexanones; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Mice, Inbred NOD; Mice, SCID; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa; RNA Interference; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Enterolactone has stronger effects than enterodiol on ovarian cancer.
Topics: 4-Butyrolactone; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Survival; Female; Humans; Lignans; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Phytoestrogens; Tumor Burden; Wound Healing | 2017 |
Apoptotic cell death induced by Z-Ligustilidein human ovarian cancer cells and role of NRF2.
Topics: 4-Butyrolactone; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Survival; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Membrane Potential, Mitochondrial; NF-E2-Related Factor 2; Ovarian Neoplasms; Reactive Oxygen Species; Transcription, Genetic | 2018 |
Flaxseed reduces the pro-carcinogenic micro-environment in the ovaries of normal hens by altering the PG and oestrogen pathways in a dose-dependent manner.
Topics: 4-Butyrolactone; Animals; Anticarcinogenic Agents; Chickens; Cyclooxygenase 1; Cyclooxygenase 2; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1B1; Cytochrome P-450 CYP3A; Diet; Dietary Supplements; Dinoprostone; Estrogen Receptor alpha; Estrogens; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Female; Flax; Hydroxyestrones; Lignans; Liver; Ovarian Neoplasms; Ovary; RNA, Messenger | 2015 |
Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells.
Topics: 4-Butyrolactone; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Fatty Acid Synthase, Type I; Female; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Ovarian Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2 | 2009 |
Overexpression of fatty acid synthase in Middle Eastern epithelial ovarian carcinoma activates AKT and Its inhibition potentiates cisplatin-induced apoptosis.
Topics: 4-Butyrolactone; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Ovarian Epithelial; Cisplatin; Drug Synergism; Fatty Acid Synthases; Female; Humans; Immunohistochemistry; Mice; Mice, Nude; Middle Aged; Middle East; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Proto-Oncogene Proteins c-akt; RNA Interference; Tissue Array Analysis; Xenograft Model Antitumor Assays; Young Adult | 2011 |
Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer.
Topics: 4-Butyrolactone; Adaptor Proteins, Signal Transducing; Apoptosis; Cell Cycle Proteins; Cell Proliferation; Chromones; ErbB Receptors; Fatty Acid Synthases; Female; Gene Expression Regulation, Neoplastic; Humans; Lipogenesis; Morpholines; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Proteolysis; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Ubiquitination | 2011 |
Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells.
Topics: 4-Butyrolactone; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Line; Cell Size; Cell Survival; Cerulenin; Fatty Acid Synthases; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Ovarian Neoplasms; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction; Transcription Factors; Trastuzumab | 2004 |
Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells.
Topics: 4-Butyrolactone; Animals; Apoptosis; Blotting, Western; Cell Line, Tumor; Enzyme Activation; Enzyme Inhibitors; Fatty Acid Synthases; Feedback, Physiological; Female; Humans; Immunohistochemistry; Mice; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoric Monoester Hydrolases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; RNA, Small Interfering; Tumor Suppressor Proteins | 2005 |
10-Demethoxystegane, a new lignan from Steganotaenia araliacea.
Topics: 4-Butyrolactone; Antineoplastic Agents, Phytogenic; Apiaceae; Chromatography, High Pressure Liquid; Colonic Neoplasms; Female; Humans; Inhibitory Concentration 50; Lignans; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Ovarian Neoplasms; Plants, Medicinal; Spectrophotometry, Infrared; Spectrophotometry, Ultraviolet; Tumor Cells, Cultured | 2001 |